Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000403045

Medchemexpress LLC Naquotinib mesylate | 1448237-05-5 | 98.1% | 658.81 | 25 MG
SDP

Catalog No. 5000403045
Encompass_Preferred

Naquotinib mesylate (ASP8273 mesylate) is an orally available, mutant-selective, and irreversible EGFR inhibitor that demonstrates inhibitory concentrations (IC50s) ranging from 8 to 33 nM against EGFR mutants and 230 nM for wild-type EGFR. It effectively inhibits the growth of various EGFR-dependent non-small cell lung cancer cell lines, including those with exon 19 deletion and T790M resistance mutations. The compound selectively targets the phosphorylation of EGFR and its downstream signaling pathways, such as ERK and Akt, at concentrations as low as 10 nM in sensitive cell lines. Additionally, oral administration of this compound induces dose-dependent tumor regression in several xenograft models.

  • Orally available
  • Mutant-selective EGFR inhibitor
  • Irreversible EGFR inhibitor
  • Inhibits phosphorylation of EGFR and downstream signal pathway, ERK and Akt
  • Induces tumor shrinkage in EGFR mutated tumor models

Catalog No. 50-004-03045 Supplier Medchemexpress LLC Supplier No. 25MGHY19803
May include imposed supplier surcharges.
Add to Cart
Add to Cart

missing translation for 'validMainframeMsg'

Naquotinib mesylate (ASP8273 mesylate) is an orally available, mutant-selective, and irreversible EGFR inhibitor that demonstrates inhibitory concentrations (IC50s) ranging from 8 to 33 nM against EGFR mutants and 230 nM for wild-type EGFR. It effectively inhibits the growth of various EGFR-dependent non-small cell lung cancer cell lines, including those with exon 19 deletion and T790M resistance mutations. The compound selectively targets the phosphorylation of EGFR and its downstream signaling pathways, such as ERK and Akt, at concentrations as low as 10 nM in sensitive cell lines. Additionally, oral administration of this compound induces dose-dependent tumor regression in several xenograft models.

  • Orally available
  • Mutant-selective EGFR inhibitor
  • Irreversible EGFR inhibitor
  • Inhibits phosphorylation of EGFR and downstream signal pathway, ERK and Akt
  • Induces tumor shrinkage in EGFR mutated tumor models

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.